Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01254045 · ClinicalTrials.gov registry record · Phase 2
Double-blind Placebo Controlled Study of Oxytocin in Fragile X Syndrome
A Phase 2 study, sponsored by Stanford University.
- Completed
- Registry status
- Phase 2
- Development phase
- 10
- Enrollment target
NCT01254045: Completed Phase 2 study, sponsored by Stanford University.
NCT01254045 is a Phase 2 study that has completed, run by Stanford University. The registered enrollment target is 10 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01254045, a Phase 2 study, has completed, sponsored by Stanford University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 10 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether the medication oxytocin is an effective and tolerable treatment in adolescent males with fragile X syndrome (FraX) for improving socially appropriate behaviors and reducing social anxiety.
Interventions
- DRUG placebo
- DRUG oxytocin 24IU
- DRUG oxytocin 48IU
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2007-02 |
| Est. Completion | 2010-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01254045
The ClinicalTrials.gov registry entry for NCT01254045 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which placebo is the first listed.
NCT01254045 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01254045 about?
NCT01254045 is a clinical study titled "Double-blind Placebo Controlled Study of Oxytocin in Fragile X Syndrome". The purpose of this study is to determine whether the medication oxytocin is an effective and tolerable treatment in adolescent males with fragile X syndrome (FraX) for improving socially appropriate behaviors and reducing social anxiety.
What is the current status of trial NCT01254045?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 10 participants. The study started on 2007-02. Estimated completion is 2010-01.
What interventions are being tested in trial NCT01254045?
The interventions under investigation include: placebo (DRUG), oxytocin 24IU (DRUG), oxytocin 48IU (DRUG).
Who is sponsoring clinical trial NCT01254045?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.